Spectrum Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Spectrum Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count).

52 total trials 1 currently recruiting 28 completed early-phase tilt top decile by trial count

Spectrum Pharmaceuticals: 52 sponsored US clinical trials, 1 recruiting.

Spectrum Pharmaceuticals sponsors 52 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 28 completed. 16 of these trials are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Phosphate Binding Capacity, with 1 trials.

Top-decile sponsor footprint

Spectrum Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

28 of 51 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (54.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

52 total, page 1 of 2

RECRUITING Phase 2

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

NCT04570423
COMPLETED Phase 1

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

NCT04981704
COMPLETED Phase 1

Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects

NCT04436562
COMPLETED Phase 1

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

NCT04187898
TERMINATED Phase 2

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

NCT04172597
TERMINATED Phase 1

A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

NCT03804515
TERMINATED Phase 2

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

NCT03744715
TERMINATED Phase 1

A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

NCT03429101
TERMINATED Phase 2

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

NCT03318939
TERMINATED Phase 3

A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)

NCT03224182
COMPLETED Phase 1

Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

NCT03135951
COMPLETED Phase 3

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

NCT02953340
TERMINATED Phase 1

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

NCT02519270
COMPLETED Phase 2

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

NCT02659514
COMPLETED Phase 3

SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)

NCT02643420
TERMINATED Phase 3

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

NCT02563561
TERMINATED Phase 2

Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)

NCT01741155
TERMINATED Phase 2

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

NCT01773785
COMPLETED Phase 2

Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

NCT01724866
TERMINATED Phase 3

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

NCT01662102
TERMINATED Phase 2

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

NCT01587144
TERMINATED Phase 3

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

NCT01510184
COMPLETED Phase 1

Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb

NCT01560884
TERMINATED Phase 3

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL

NCT01439347
TERMINATED Phase 3

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT01469221
TERMINATED Phase 2

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

NCT01549886
TERMINATED Phase 3

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

NCT01420679
TERMINATED Phase 3

Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

NCT01410565
COMPLETED Phase 1

A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies

NCT01317927
COMPLETED Phase 2

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

NCT01252693
COMPLETED Phase 2

Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

NCT00998946
COMPLETED Phase 2

Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT00865969
TERMINATED Phase 2

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

NCT00743184
COMPLETED Phase 1

Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors

NCT00765973
COMPLETED Phase 1

Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

NCT00656786
COMPLETED Phase 1

A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma

NCT00613691
COMPLETED Phase 2

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

NCT00606502
COMPLETED Phase 2

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

NCT00506142
TERMINATED Phase 1

Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00558727
COMPLETED Phase 3

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

NCT00598806
COMPLETED Phase 2

Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia

NCT00495079
COMPLETED Phase 3

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)

NCT00461591
COMPLETED Phase 2

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

NCT00427219
TERMINATED Phase 3

Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)

NCT00384111
COMPLETED Phase 1

Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

NCT00364676
TERMINATED Phase 3

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

NCT00322218
COMPLETED Phase 2

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00090090
TERMINATED Phase 1

Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness

NCT00088023
COMPLETED Phase 3

Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer

NCT00083304
COMPLETED Phase 1

10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

NCT00052442
Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 16
Phase 2 20
Phase 3 16

Therapeutic Areas

Phosphate Binding Capacity 1
Benign Prostatic Hypertrophy 1
EGFR Inhibitor-associated Rash 1
Safety 1
Acute Lymphoblastic Leukemia (ALL) 1
Carcinoma 1
Solid Tumors 1
Peripheral T-Cell Lymphoma 1
Metastatic Cancer 1
Bladder Cancer 1

What is open in the Spectrum Pharmaceuticals pipeline

1 recruiting of 52 indexed (2% open); 28 completed (54%).

Phase mix: 16 late (III/IV) vs 36 early (I/II) (early-phase heavy).

Top condition: Phosphate Binding Capacity (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Spectrum Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 52 registered trials and 2% open enrollment, not the therapeutic-area sidebar.

Spectrum Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200250300 0%5%10%15% Total trials Recruiting share Spectrum PharmaceuticalsAlbany Medical CollegeBurzynski Research InstituteDr. Reddy's Laboratories LimitedPTC TherapeuticsSociété des Produits Nestlé (SPN)Sanofi Pasteur, a Sanofi CompanyCarelon ResearchAlcon Research
Spectrum Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Spectrum Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 52 trials (± recruiting share)

Sponsors near 2% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Spectrum Pharmaceuticals page

52 registered trials is a research-attention snapshot, not an endorsement of Spectrum Pharmaceuticals or any single study.

  • 1 of Spectrum Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Phosphate Binding Capacity is the condition Spectrum Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Phosphate Binding Capacity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Spectrum Pharmaceuticals pipeline card: 52 registered trials from official public datasets.Report a data error.